retatrutide clinical trials usa Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 trials, is being sold openly across the internet and prescribed by licensed physicians online and TRIUMPH 5: Retatrutide vs Tirzepatide

What this post covers: Where GLP-1 receptors sit in the brain and why that matters for reward and compulsion The clinical trial pipeline for GLP-1 agonists in addiction (alcohol, nicotine, opioids) Why anhedonia may be a dosing problem, not a drug problem, and the ziprasidone parallel Real-world observations from low-dose tirzepatide combined with ketogenic diets The scope-of-practice question: should psychiatrists be prescribing GLP-1 agonists

Timing Optional Marker Urinalysis Why it matters Can add basic kidney and hydration context when there are urinary symptoms or kidney concerns

Eine klinische Studie aus dem Jahr 2024 zur PDRN-Wirksamkeit (PubMed: 38842633) besttigte, dass die wchentliche Anwendung ber 12 Wochen statistisch signifikante Verbesserungen der Haardichte erzielt

Results GLP-1 RA treatment consistently reduced body weight, BMI, and waist circumference across all time points